Stock TLPH TALPHERA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Talphera, Inc.

Equities

TLPH

US00444T2096

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-15 pm EDT 		5-day change 1st Jan Change
1.215 USD +19.12% Intraday chart for Talphera, Inc. +16.83% +65.31%
May. 14 Transcript : Talphera, Inc., Q1 2024 Earnings Call, May 14, 2024
Mar. 06 Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Talphera, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a41eb3016b63a884cd4e437f778fc97._o9HR1hnb6taXlD3DmDTNhR3JVBIj2HVEpiLMAsy_6k.it11JGwEOcFoZyGQbw2rd2cnHRcYuxi6e9vORVN3qZDJ1nMYAAIMnhknAQ~400c1a3c59df10d695791b7e794f191e

Analyst Recommendations on Talphera, Inc.

Alliance Global Initiates AcelRx Pharmaceuticals at Buy With $4.25 Price Target MT
HC Wainwright Adjusts AcelRx Pharmaceuticals Price Target to $5 From $8, Maintains Buy Rating MT
HC Wainwright Upgrades AcelRx Pharmaceuticals to Buy From Neutral, Price Target is $8 MT
HC Wainwright Downgrades AcelRx Pharmaceuticals to Neutral from Buy MT
Cantor Fitzgerald Lowers Price Target for AcelRx Pharmaceuticals to $4 From $9, Maintains Overweight Rating MT
ACELRX PHARMACEUTICALS : HC Wainwright Adjusts Price Target on AcelRx Pharmaceuticals to $5 From $7, Maintains Buy Rating MT
AcelRx Pharmaceuticals, Inc. Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of Dsuvia for Acute Pain in Hospital Settings CI
ACELRX PHARMACEUTICALS : Credit Suisse Adjusts AcelRx Pharmaceuticals' Price Target to $0.83 From $0.84, Reiterates Underperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.215 USD
Average target price
4.417 USD
Spread / Average Target
+263.51%
High Price Target
6 USD
Spread / Highest target
+393.83%
Low Price Target
3 USD
Spread / Lowest Target
+146.91%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Talphera, Inc.

Alliance Global Partners
HC Wainwright
Cantor Fitzgerald

Ratings for Talphera, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TLPH Stock
  4. Consensus Talphera, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW